RANZCR 2025: Medical specialists converge to examine Australian radiotherapy breakthrough
Australian researchers last night revealed human clinical data for a world-first pan-cancer biomarker assay, RadnostTM,…
Browsing: Featured Events
ESMO 2025: Men with BRCA1 and BRCA2 gene mutations should get annual prostate cancer screening
Scientists at The Institute of Cancer Research, London, are calling for targeted screening after finding…
ESMO 2025: New generation of antibody-drug conjugates shows promise in early-stage disease
The ESMO Congress 2025 has seen pivotal studies unveiling compelling evidence that a new class of…
ESMO 2025: Dual targeted therapy shows promise in previously treated advanced kidney cancer
Results from a trial presented at ESMO 205 have shown that a targeted therapy combination improved…
ESMO 2025: Trial results show belzutifan shrinks rare neuroendocrine tumours and improves symptoms
A multicenter Phase II clinical trial has demonstrated significant tumour shrinkage and disease control in patients…
ESMO 2025: Novel treatment combination improves progression-free survival in metastatic, oestrogen-receptor-positive HER-2-negative breast cancer
Patients with oestrogen-receptor-positive HER-2-negative advanced breast cancer showed significantly improved progression-free survival when treated with…
ESMO 2025: Chemo combination boosts overall survival in patients with EGFR-mutant NSCLC
Treatment with osimertinib plus a platinum–pemetrexed chemotherapy combination resulted in statistically significant and clinically meaningful…
ESMO 2025: Immunotherapy after surgery shows promise in treating rare, aggressive skin cancer
A drug that harnesses the immune system to attack cancer cells has proved successful in…
AGITG ASM 2025: Special Podcast Preview
A sneak preview podcast of what to expect from the AGITG’s 2025 ASM!
ASTRO 2025: Patient-reported outcome analysis of NRG Oncology trial in limited-stage small cell lung cancer suggests quality of life benefit with twice – (vs once -) daily radiation
Previously, the primary endpoint results of the NRG-LU005 study assessing the addition of the immunotherapy…